Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 94 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Day-to-Day Function Clear all
Completed Phase 4 Interventional Results available

Cognitive Outcomes in Stable Renal Transplant Patients Switched fromTacrolimus to Envarsus XR™

NCT04838288
View directory record Official record
Conditions
Renal Transplant
Interventions
Change from Prograf to Envarsus XR
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

NCT01979952
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Matching Placebo, Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Danbury, Connecticut • Sarasota, Florida • Skokie, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Not applicable Interventional Results available

Reducing Suicide Risk in Adolescents and Young Adults Via a Psychobehavioral Intervention to Regularize Daily Rhythms

NCT05317481
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Mood Disorders, Suicide, Suicidal Ideation
Interventions
BE-SMART-DR, psychoeducational control comparator condition (CC)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
16 Years to 29 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 10, 2026, 8:10 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cognitive Control and Physical Exercise

NCT01183819
View directory record Official record
Conditions
Cognitive Function, Day-to-Day Function
Interventions
Space Fortress, Aerobic Exercise, Stretching, Control Games
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
60 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Sep 10, 2026, 8:10 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.

NCT04899271
View directory record Official record
Conditions
New-onset Type 1 Diabetes
Interventions
Ladarixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Aurora, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Assess the Effect of Daily Treatment of Vardenafil 20mg or Sildenafil 100mg and Placebo on Sperm Function

NCT00655590
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Levitra (Vardenafil, BAY38-9456), Sildenafil, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
25 Years to 64 Years · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
18
States / cities
Phoenix, Arizona • Tempe, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 10, 2026, 8:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Automated IADL Sensing to Refine Measurement of Older Adult Daily Activity

NCT07585864
View directory record Official record
Conditions
Cognitive Ability General, Functional Abilities
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
75 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

NCT01569464
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Rotigotine, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Jasper, Alabama • Gilbert, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01706328
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease

NCT01627327
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate/vilanterol 100/25mcg, tiotropium bromide 18mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
11
States / cities
Newport Beach, California • Coeur d'Alene, Idaho • Charlotte, North Carolina + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 10, 2026, 8:10 AM EDT
Terminated Not applicable Interventional

A Pilot Study of a Strategy and Computer-based Intervention to Enhance Daily Cognitive Functioning After Stroke

NCT04098835
View directory record Official record
Conditions
Stroke
Interventions
ASCEND
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
45 Years to 89 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

NCT01177410
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Placebo, Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Sherwood, Arkansas • Anaheim, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 4 Interventional

Sexual Functioning Study With Antidepressants

NCT00316160
View directory record Official record
Conditions
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions
Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
45
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

NCT03573817
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Revefenacin, Placebo, Formoterol
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 2 Interventional

Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*

NCT00511368
View directory record Official record
Conditions
HIV Infections
Interventions
matching placebo, Bevirimat
Drug
Lead sponsor
Myrexis Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2010 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers

NCT01188317
View directory record Official record
Conditions
Healthy Volunteer
Interventions
aleglitazar, placebo, ibuprofen
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 2 Interventional

Tricaprilin in Mild to Moderate Alzheimer's Disease

NCT00142805
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Tricaprilin, Placebo
Drug · Other
Lead sponsor
Cerecin
Industry
Eligibility
50 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
25
States / cities
Phoenix, Arizona • Cerritos, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2020 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety, Tolerability, Kinetics and Efficacy Study of Hoodia Gordonii Purified Extract (PYM50717)

NCT01306422
View directory record Official record
Conditions
Appetite Depressant, Overweight, Body Weight
Interventions
Hoodia gordonii purified extract (H.g.PE), Placebo yogurt drink
Other
Lead sponsor
Unilever R&D
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

NCT01559116
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Placebo, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Jasper, Alabama • Easley, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance

NCT00711516
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Burlingame, California • San Diego, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Not applicable Interventional

Role of Exercise in Diastolic Heart Failure

NCT01047631
View directory record Official record
Conditions
Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
Functional circuit training and lifestyle counseling, Health education and independent walking
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 10, 2026, 8:10 AM EDT
Terminated Phase 2 Interventional

HT-3951 vs. Placebo in Stroke Rehabilitation

NCT02530307
View directory record Official record
Conditions
Ischemic Stroke
Interventions
HT-3951, Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
21 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Downey, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioenergetics and Muscle Function Improvement With AMAZ-02 in Elderly Skeletal Muscle (ENERGIZE Trial)

NCT03283462
View directory record Official record
Conditions
Mitochondrial Function, Bioenergetics, Muscle Function, Aging
Interventions
Mitopure, Placebo
Dietary Supplement
Lead sponsor
Amazentis SA
Industry
Eligibility
65 Years to 90 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 10, 2026, 8:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study of Visual Effects of Erectile Dysfunction Medications Dosed Daily for Six Months

NCT00333281
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 65 Years · Male only
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 24, 2007 · Synced Sep 10, 2026, 8:10 AM EDT